LXRX Q3 2025 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+710.4% YoY

Gross Profit

$14M99.9% margin

Operating Income

-$12M-85.9% margin

Net Income

-$13M-90.0% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

-50.9%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$206M

Total Liabilities

$86M

Stockholders' Equity

$120M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$2M	+710.4%
Gross Profit	$14M	$2M	+744.1%
Operating Income	-$12M	-$64M	+80.9%
Net Income	-$13M	-$65M	+80.3%

Revenue Segments

License

$13M93%

Product

$1M7%